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Abstract
Purpose: The purpose of this study was to compare the in vitro effects of triamcinolone acetonide (TA) and
dexamethasone sodium phosphate (DEX) on human lens epithelial cells (HLE B-3).
Methods: HLE B-3 cells were exposed for 24 h to commercially available TA (c-TA) and dimethylsulfoxidesolubilized TA (s-TA). The cells were treated with 1,000 (clinical dose), 750, 500, 200, and 100 mg/mL concentrations of c-TA, s-TA, and supernatant for 24 h. The cells were also treated with DEX at 2, 1, 0.5, 0.2, 0.1 (clinical
dose), and 0.05 mg/mL. Cell viability, caspase-3/7 activity, and DNA fragmentation analyses were performed.
Results: The mean cell viabilities of HLE B-3 after exposure to c-TA at 1,000, 750, 500, 200, and 100 mg/mL were
significantly reduced compared with control untreated cells. The s-TA also significantly reduced cell viability at
1,000, 750, and 500 mg/mL compared with dimethylsulfoxide control. The supernatant did not reduce cell
viability. Caspase-3/7 activity significantly increased after treatment with c-TA and s-TA. DNA laddering
revealed bands at 200 bp intervals with both c-TA at ‡ 100 mg/mL and s-TA at ‡ 500 mg/mL. The cell viabilities of
HLE B-3 after 24 h exposure to DEX were significantly reduced at 2 and 1 mg/mL but not at lower concentrations tested. Caspase-3/7 activities in HLE B-3 cells were not increased significantly after treatment with DEX
at any dose tested. DNA laddering did not reveal any band at any dose tested.
Conclusion: This study showed that TA at its clinical dose (1,000 mg/mL) in both commercial preparation and
solubilized forms decrease HLE B-3 cell viability through an apoptotic pathway. DEX at its clinical dose (0.1 mg/
mL) does not decrease cell viability or cause any increase of caspase-3/7 activity. This study suggests that for
long-term sustained-release devices, DEX may be less damaging to human lens cells than TA.

Introduction

T

he recent focus on the angiostatic and antipermeability properties of steroids has encouraged clinicians
to greatly extend the use of intravitreal corticosteroids in a
variety of ocular conditions. Triamcinolone acetonide (TA)
is an insoluble crystalline steroid that acts as a depot when
injected intravitreally. For its prolonged duration of action,
TA is broadly used in treatment of a variety of ocular diseases. Intravitreal TA (IVTA) is extensively used in treat-

ment of macular edema due to diabetic retinopathy,1,2
venous occlusive disease,3 ocular inflammation,4,5 and
choroidal neovascularization.6 The anti-inflammatory potency of TA is similar to that of methylprednisolone but
significantly less compared with that of dexamethasone.7
The biological half-life of parenterally administered TA is
18–36 h,8 whereas the mean elimination half-life in nonvitrectomized eyes is 18.6 days, with measurable concentrations of TA for *3 months after intravitreal injection in
nonvitrectomized eyes.8
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Dexamethasone sodium phosphate (DEX) is also clinically
used to reduce intraocular inflammation; but, because it is
only available in a soluble form, its duration of action is
much less than that of TA.9 DEX has a half-life of *3 h in the
rabbit eye, leading to clearance from the vitreous after *3
days.9 For its short duration of action, intravitreal DEX has
enjoyed a limited role in the management of chronic and/or
refractory posterior segment diseases. However, advances in
new sustained-release devices containing DEX have brought
recent excitement in the use of DEX for management of a
variety of chronic/refractory ocular conditions such as
macular edema.10
Studies have shown that although the steroids are injected
into the vitreous, there is diffusion into the anterior chamber,
and as a result, elevated concentrations of the steroids can be
found in that region.8,11,12 Under these circumstances, the
lens epithelial cells would be exposed to high concentrations
of steroids, which may have a negative effect because the
terminal differentiation of the epithelial cells into lens fibers
is essential for development and growth of the lens.13–16
Therefore, steroid-induced damage to these parental lens
cells could disrupt the normal biological processes and
contribute to cataract formation.
Adverse events typically associated with corticosteroid
therapy include cataract formation and increased intraocular
pressure.17,18,19 The purpose of this study was to compare
the in vitro effects of 2 steroids that are used clinically, TA
and DEX, to determine their cytotoxic effects upon a human
lens epithelial cell line (HLE B-3).

Methods
Cell culture
HLE B-3 cells (provided by Usha P. Andley) were grown in
tissue culture in minimum essential medium containing Eagle’s salts, l-glutamine, gentamicin (50 mg/mL), and 20% fetal
bovine serum. The cells were plated in 6- and 24-well plates
(Becton Dickinson Labware, Franklin Lakes, NJ) for cell viability (5.5 · 105 cells per well) and caspase-3/7 (1.5 · 105 cells
per well) assays, respectively. Passages 15–20 were used for
the experiments. As there are variations in enzyme activity
with passage and time, experiments were performed in
triplicates and all the experiments were repeated 3 times.

Exposure to drug
Commercially available TA (c-TA; Kenalog; BMS,
Princeton, NJ) was centrifuged at 5,000 rpm for 1 min and
the supernatant was removed. To generate the solubilized
TA (s-TA), the pellet was resuspended in equivalent amounts
of dimethylsulfoxide (DMSO) to achieve the same concentration of TA found in the commercial suspension. The cells
were treated for 24 h with 1,000 (clinical dose), 750, 500, 200,
and 100 mg/mL concentrations of c-TA, s-TA, and the supernatant. Other cells were treated for 24 h with DEX (APP,
Schaumburg, IL) at 2,000, 1,000, 500, 200, 100 (clinical dose),
and 50 mg/mL concentrations.

SHARMA ET AL.
37C for 5 min. The cells were centrifuged at 1,000 rpm for
1 min and then resuspended in 1 mL of culture medium.
Automated cell viability analysis was performed (ViCell
analyzer; Beckman Coulter, Inc., Fullerton, CA). The analyzer performed an automated trypan blue dye-exclusion
assay, generating percentages of viable cells.

Caspase-3/7 assay
Caspase-3/7 activities were detected with carboxyfluorescein apoptosis detection kits (FLICA; Immunochemistry
Technologies LLC, Bloomington, MN). At the designated time
period, the wells were rinsed briefly with fresh culture media,
replaced with 300 mL/well of 1 · FLICA solution in culture
media, and incubated at 37C for 1 h under 5% CO2. Cells
were washed with phosphate-buffered saline. The following
controls were included: untreated HLE B-3 cells without
FLICA were used as a background control; untreated HLE B-3
cells with FLICA for comparison of caspase activity of treated
cells; wells without cells with buffer alone; tissue culture plate
wells without cells with culture media + DMSO to exclude
cross-reaction of FLICA with DMSO + culture media; and
HLE B-3 cells with DMSO and FLICA to account for any
cross-fluorescence between untreated cells and DMSO.
Quantitative calculations of caspase activities were performed with a fluorescence image scanning unit instrument
(FMBIO III; Hitachi, Yokohama, Japan). The caspase activity
was measured as the average signal intensity of the fluorescence of the pixels in a designated spot, that is, mean
signal intensity.

DNA fragmentation assay
HLE B-3 cells (5 · 106) were plated overnight in 100-mm
dishes and then incubated for another 24 h with c-TA, s-TA,
and DEX in serum-free medium. DNA was extracted
(QIAamp DNA Micro kit; Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Samples were
separated by electrophoresis on 3% agarose gels and stained
with 5% ethidium bromide. A 100-bp marker was used and
images were captured with a fluorescence image scanning
instrument (FMBIO III; Hitachi).

Statistical analysis
Data were subjected to statistical analysis by ANOVA
(Prism, ver. 3.0; GraphPad Software, Inc., San Diego, CA).
Newman–Keuls multiple-comparison test was done to
compare the data within each experiment. P < 0.05 was considered statistically significant. Error bars in the graphs
represent SEM, with experiments performed in triplicate.

Results
Cell viability studies

Cell viability assay

c-TA preparation. The mean cell viabilities of HLE B-3 after
exposure to c-TA at 1,000, 750, 500, 200, and 100 mg/mL were
26.3 – 5.8 (P < 0.001), 34.0 – 3.2 (P < 0.001), 43.6 – 3.3 (P < 0.001),
54.3 – 11.7 (P < 0.001), and 71.6 – 4.4 (P < 0.01), respectively,
compared with control untreated cells (89.7 – 0.5; Fig. 1A).

Cell viability assay was performed as previously described.20 Briefly, cells harvested from the 6-well plates by
treatment with 0.2% trypsin–EDTA were then incubated at

s-TA preparation. HLE B-3 cells exposed to s-TA also had
a significantly reduced mean cell viability of 20.1 – 2.5
(P < 0.001), 30.4 – 6.6 (P < 0.001), and 36.2 – 2.4 (P < 0.001) at
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93.7 – 2.9 (P > 0.05), respectively, compared with control untreated cells (94.9 – 0.9) (Fig. 1C).

Caspase-3/7 activity
c-TA preparation. The mean caspase-3/7 activity of HLE
B-3 after 24 h exposure to c-TA at 1,000, 750, 500, 200, and
100 mg/mL was 13,407.0 – 1,079.7 (P < 0.001), 13,848.0 –
1,496.3 (P < 0.001), 11,660.0 – 590.3 (P < 0.001), 11,701.3 – 611.7
(P < 0.001), and 10,814.6 – 947.3 (P < 0.001), respectively,
compared with control untreated cells (2,600.0 – 510.9)
(Fig. 2A).
s-TA preparation. Caspase-3/7 activity in HLE B-3 significantly increased after treatment with s-TA for 24 h. The
cells treated with s-TA 1,000, 750, 500, 200, and 100 mg/mL
showed mean fluorescence of 10,160.0 – 498.2 (P < 0.001),
10,886.5 – 1,429.0 (P < 0.001), 8,308.5 – 485.7 (P < 0.001), 7,632.0 –
914.9 (P < 0.001) and 2,932.5 – 830.8 (P > 0.05), respectively.
Values for untreated cells and DMSO-equivalent cultures for
1,000, 750, 500, 200, and 100 mg/mL were 3,479.0 – 281.4 and
3,232.7 – 24.5, 3,057.7 – 222.9, 3,325.2 – 883.6, 3,867.5 – 116.6,
and 3,215.0 – 487.9, respectively (Fig. 2B).

TA supernatant

FIG. 1. (A) c-TA causes dose-related cell viability loss of
HLE B-3 cells, starting at a concentration of 100 mg/mL
(*P < 0.001). (B) s-TA treatment causes dose-related decrease
in cell viability of HLE B-3 cells, starting at a concentration of
500 mg/mL (*P < 0.001). (C) DEX causes dose-related cell viability loss of HLE B-3 cells, beginning at a concentration of
500 mg/mL (*P < 0.001). c-TA, commercially available triamcinolone acetonide; DEX, dexamethasone sodium phosphate;
HLE, human lens epithelial; s-TA, solubilized TA; DMSO,
dimethylsulfoxide.
1,000, 750, and 500 mg/mL, respectively, compared with
equivalent DMSO control cultures. At 200 and 100 mg/mL,
mean cell viabilities were 76.6 – 7.2 (P > 0.05), and 85.3 – 3.4
(P > 0.05), respectively, compared with equivalent DMSO
control cultures. Values of DMSO controls at 1,000, 750, 500,
200, and 100 mg/mL were 65.5 – 13.0, 69.0 – 7.4, 81.2 – 4.0,
86.9 – 4.7, and 87.6 – 0.0, respectively. Untreated control culture cell viability was 89.3 – 3.9 (Fig. 1B).

TA supernatant
The supernatant alone did not reduce the viability of HLE
B-3 cells at any concentration. The mean cell viabilities at
1,000, 750, 500, 200, and 100 mg/mL were 85.9 – 2.7 (P > 0.05),
85.3 – 4.6 (P > 0.05), 85.3 – 4.3 (P > 0.05), 84.8 – 6.4 (P > 0.05),
and 88.1 – 3.6 (P > 0.05), respectively, compared with control
untreated cells (89.4 – 2.7) (figure not shown).

Caspase-3/7 activities in HLE B-3 cells were not increased
significantly after treatment with supernatant at all concentrations tested. The mean caspase-3/7 activity of HLE B-3
after 24 h exposure to TA supernatant at 1,000, 750, 500, 200,
and 100 mg/mL and untreated cells were 3,999.80 – 454.5
(P > 0.05), 3,720.9 – 374.6 (P > 0.05), 3,746.0 – 502.0 (P > 0.05),
4,069.0 – 239.0 (P > 0.05), and 3,910.0 – 579.8276 (P > 0.05),
respectively, compared with control untreated cells
(3,650.5 – 637.1) (figure not shown).

Dexamethasone sodium phosphate
Caspase-3/7 activity in HLE B-3 was not significantly increased after treatment with DEX for 24 h. The mean caspase3/7 activity of HLE B-3 after 24 h exposure to DEX at 2,000,
1,000, 500, 200, 100 (clinical dose), and 50 mg/mL were
3,998.0 – 457.9 (P > 0.05), 4,279.1 – 521.8 (P > 0.05), 3,815.7 –
714.8 (P > 0.05), 4,470.6 – 1,484.3 (P > 0.05), 3,840.5 – 690.8
(P > 0.05), and 4,780.5 – 649.8 (P > 0.05), respectively, compared with control untreated cells (3,983.6 – 730.2) (Fig. 2C).

DNA fragmentation assay
c-TA preparation. Caspase-3/7 is the hallmark of apoptosis because it is the final common pathway of apoptosis.
To verify apoptotic activity, DNA fragmentation analysis
was performed, which showed DNA bands laddered in
*200 bp increments, consistent with apoptosis (Fig. 3A).
s-TA preparation. DNA fragmentation analysis showed
bands in *200 bp increments, consistent with apoptosis (Fig.
3B).

Dexamethasone sodium phosphate
The mean cell viabilities of HLE B-3 after 24 h exposure to
DEX at 2,000, 1,000, 500, 200, 100 (clinical dose), and 50 mg/
mL were 14.8 – 0.8 (P < 0.001), 23.6 – 0.2 (P < 0.001), 80.1 – 1.3
(P < 0.001), 92.4 – 0.3 (P > 0.05), 93.1 – 2.9 (P > 0.05), and

Dexamethasone sodium phosphate
DNA laddering did not reveal any band, corroborating the
lack of apoptosis evidenced by the absence of caspase-3/7
activity (Fig. 3C).
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FIG. 2. (A) c-TA treatment causes increased caspase-3/7 activity at all concentrations
tested
(*P < 0.001).
(B)
Treatment with s-TA causes higher levels
of caspase-3/7 activity at all concentrations tested (*P < 0.001) except 100 mg/mL
(P > 0.05). (C) DEX did not show caspase3/7 activity at any of the concentrations
tested (P > 0.05).

Discussion
The use of intravitreal corticosteroids in the management
of a variety of ocular conditions has recently gained widespread acceptance. Formation and/or progression of cataract
are common complications of intravitreal steroids.19,21,22 In a
study by Jonas et al., IVTA in an elderly population of patients led to clinically significant cataract formation and
eventual cataract surgery in about 15%–20% of eyes within 1
year.23 A single IVTA injection was noted to induce posterior
subcapsular cataract development, whereas multiple injections result in all-layer cataract progression.21 Although
cataract is a reversible cause of vision loss, with the recent
improvements in the cataract surgery techniques, it is now
considered to be a relatively low-risk procedure, and it is
generally associated with more long-term complications in
patients with chronic posterior segment diseases.24,25 It is
therefore of clinical significance to identify whether 1 steroid
formulation is less cataractogenic than another.
Loss of cell viability resulting from triggered apoptosis or
necrosis in HLE cells has been shown to be involved in the
pathogenesis of cataract formation.26,27 Glucocorticoids induce apoptosis in hematological cells and are used as a
chemotherapeutic agent for leukemias, lymphomas, and
myeloma. Glucocorticoid-mediated apoptotic cell death

could be the final result of the negative modulation of
proinflammatory cytokines or glucocorticoid receptor alteration28,29 or may be a consequence of cell cycle arrest.30
Charakidas et al. demonstrated the presence of lens epithelial
cell apoptosis and proliferation in human age-related cortical
cataract.31 Although they found a relatively low rate of apoptotic death, which they felt was unlikely to cause significant lenticular opacity, it has been recognized that steroids
can induce apoptosis,32 and it is possible that the higher rate
of apoptotic death might lead to cataract formation. For example, Li et al. have shown that lens epithelial cell apoptosis
occurs in calcimycin-induced cataract formation.33
In our study, cell viability assays have demonstrated that
both TA and DEX have cytotoxic effects on the HLE B-3 cells
in a concentration-dependent fashion, although the effect
was more pronounced in cells treated with TA. The usual
clinical dosage of IVTA is 4 mg, and assuming that the vitreous volume is 4 mL, the intravitreal clinical concentration
of TA would be 1,000 mg/mL (assuming equal dispersion of
the drug throughout the vitreous cavity, although typically
this does not happen in a nonvitrectomized eye as the drug
tends to aggregate). Our study shows that this ‘‘clinically
equivalent’’ dose and also doses as low as 1/5 of the clinical
dose of both crystalline c-TA and s-TA decrease HLE
cell viability. In contrast, the assigned clinical dosage of
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FIG. 3. (A) DNA laddering
analysis after 24 h exposure to
c-TA. DNA bands that laddered in *200 bp increments
are consistent with apoptosis.
(B) DNA laddering analysis
after 24 h exposure to s-TA
showed bands that laddered
at *200 bp increments, which
are consistent with apoptosis.
(C) DNA laddering analysis
showed that after 24 h exposure to DEX, no bands were
observed. M, marker; CTRL,
control.

intravitreal dexamethasone is 0.1 mg/mL (100 mg/mL),
which is 10 times below the ranges that caused loss of lens
cell viability in the HLE B-3 cells. The observed greater toxic
potential of TA compared with DEX has been recently shown
by Yeung et al. in a cultured retinal pigment epithelium
(RPE) cell line.34 Although many clinical studies have shown
cataract development and progression after intravitreal use
of TA,21,35,36 to the best of our knowledge, this is the first
study comparing the effect of doses of TA and DEX used
clinically on lens epithelial cells in vitro.
Loss of cell viability can be attributed to both apoptosis
and/or necrosis. Caspase-3/7 is a key effector in the apoptosis pathway, and its activation signals the full commitment to disassembly of the cell. It is known that caspase
detects apoptotic and dying cells, but once the cell is dead it
will not be caspase positive. Because of high numbers of
dead cells at higher doses (1,000 mg/mL), we do not see dosedependant increase at higher c-TA doses. Our study demonstrates that the loss of cell viability in TA-treated HLE B-3
cells is associated with activation of caspase-3/7 pathway,
suggesting an involvement of an apoptotic mechanism,
which was then further supported by DNA fragmentation
analysis. In contrast, caspase-3/7 activities in HLE B-3 cells
were not significantly increased after treatment with DEX at
all concentrations tested. Other studies have shown that
dexamethasone causes necrosis on corneal endothelial cells,37
but it does not cause apoptosis in retinal pigment epithelial
cells.38 However, recently, Petersen et al. reported that DEX
induces caspase-3 apoptosis in HLE cells. This could be due
to difference in cell line used and different conditions of incubation. To mimic normal physiological behavior of HLE
cells, we used 20% serum for incubation and treatment,
whereas Petersen et al. used serum-free culture media during
treatment.39 Our findings indicate that the cytotoxic effects of
TA and DEX are mechanistically different. Further, lower
solubility of TA leads to slower, and perhaps unequal, dispersion in vitreous and, therefore, variable concentration at
different locations in vitreous cavity. We hypothesize that
this could add to cataractogenic toxicity of TA if higher levels
remain near the posterior pole of the lens.

We acknowledge that there are limitations to our study.
First, concentrations used in this study cannot be directly
extrapolated to clinical practice, as this study was performed
in vitro. In addition, the cells were exposed for only 24 h,
which is not the case in clinical conditions, although by
looking for subtle downstream changes such as mitochondrial membrane potential changes and caspase upregulation
we are able to detect early effects that are likely to be predictive of later damage. Third, TA drug crystals came in
direct contact with the cells, which happens in clinical conditions such as in vitrectomized eyes. However, to eliminate
the crystal contact effect, the TA was solubilized and there
was a decrease in cell viability and an increase in caspase-3/7
activity. In general, the in vitro cell toxicity experiments have
been predictive or corroborative of clinically observed toxicity with other agents such as vital dyes.20 Regardless, the
results of this study suggest that doses of TA clinically used
may be more cytotoxic to HLE cells than DEX and, hence,
perhaps, more cataractogenic. Despite having more potency,
DEX has also been shown to be less cytotoxic in other ocular
cell lines than TA.34,40–44 The varying levels of cytotoxicity
for DEX and TA may be due to differences in their chemical
formulations. TA has been shown to be more toxic than DEX
primarily because of its crystalline formulation. Although
these crystals make TA an excellent choice for long-term
drug delivery, on the other hand, these crystals have been
shown as a cause of toxicity. Szurman et al. showed that
filter-purified, nonadherent TA is nontoxic to ARPE-19 cells
at concentrations of up to 1,000 mg/mL.44 However, filtering
this compound may result in decreased efficacy of TA,
making it undesirable to use clinically. To summarize, the
decreased lens epithelial cell toxicity observed in vitro with
DEX compared with TA, combined with the greater potency
of DEX over TA, suggests that DEX may be a better option
for prolonged clinical use in the eye.
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